RTW Biotech Opportunities Ltd (LSE: RTWG), a London-listed investment fund focused on biopharmaceutical and medical technology assets, has announced the repurchase of 223,376 ordinary shares at a price of $2.45 per share on 10 November 2026. The repurchased shares will be held in treasury and will carry no voting rights. The buyback was conducted under authority granted to the company by shareholders at its Annual General Meeting in June 2026, with Jefferies International Limited acting as broker for the transaction.

Key Points

  • RTW Biotech Opportunities Ltd (LSE: RTWG) — London-listed biopharmaceutical and medtech investment fund managed by RTW Investments, LP
  • The company repurchased 223,376 ordinary shares at $2.45 per share on 10 November 2026, to be held in treasury
  • Total voting rights now stand at 318,596,971, with 27,370,469 shares held in treasury out of 345,967,440 issued ordinary shares
  • Investors should watch the pace of further buybacks ahead of the next AGM authority, expected in 2027

RTW Biotech Repurchases Shares Under June 2026 AGM Authority Permitting Up to 14.99% Buyback

The buyback was executed under a shareholder authority granted at the company's Annual General Meeting in June 2026, which permits RTW Biotech Opportunities Ltd to repurchase a maximum of 14.99% of its ordinary shares. The company notes that the actual number of shares repurchased will depend on prevailing market conditions. This authority remains in force until a new shareholder authority is granted — currently expected at the Annual General Meeting in 2027 — or until it is expressly revoked by shareholders. The company has stated it is its current intention to hold all repurchased shares in treasury rather than cancel them.

Treasury Share Holdings and Updated Voting Rights Following the 10 November Transaction

Following the settlement of the 10 November 2026 purchase, RTW Biotech Opportunities Ltd's total issued ordinary share capital stands at 345,967,440 shares. Of these, 27,370,469 ordinary shares are now held in treasury and attract no voting rights. As a result, the total number of voting rights in the company is 318,596,971. The company notes that this figure of 318,596,971 should be used by shareholders as the denominator when calculating whether they are required to disclose an interest, or a change in interest, under the FCA's Disclosure and Transparency Rules.

Jefferies International Acts as Broker With NAV Premium Restriction Applying to All Buyback Prices

RTW Biotech Opportunities Ltd has instructed Jefferies International Limited as its broker for the buyback programme, in accordance with FCA Listing Rules and the company's general repurchase authority. The company has confirmed that no maximum total consideration for the buyback has been determined. However, the announcement states that the company is prohibited from paying a price for any ordinary shares that would equate to a premium to net asset value. The buyback arrangement is managed by investment manager RTW Investments, LP, a healthcare-focused firm with scientific expertise across life-changing therapy development.